Registry of Lobbyists
Active
-
Last Updated:
2024-04-01
| Subject matters | Details | Categories |
|---|---|---|
|
Health,
Science and Technology
|
Communicating with government officials about data exclusivity, more specifically as it relates to the use of natural health products in biopharmaceutical preparations.
|
Policies or Program
|
|
Health,
Labour
|
Communicating with government officials about federal healthcare benefits, including those delivered by members of the Federal Healthcare Partnership ("FHP"), such as the Department of National Defence, the Department of Indigenous Services, the Royal Canadian Mounted Police and the Department of Veterans Affairs.
|
Policies or Program
|
|
Health
|
Communicating with government officials about guidance, policies and documents issued by the Office of Patented Medicines and Liaison ("OPML") within the Office of Submissions and Intellectual Property, Therapeutic Products Directorate ("TPD").
|
Policies or Program
|
|
Health,
Science and Technology
|
Communicating with government officials about initiatives, partnerships research and programs by the Canadian Institutes of Health Research ("CIHR").
|
Policies or Program
|
|
Health,
Intellectual Property,
International Trade
|
Communicating with government officials about international trade matters, including intellectual property provisions under the Canada-European Union Comprehensive Economic and Trade Agreement (“CETA”) and the Trans-Pacific Partnership (“TPP”).
|
Legislative Proposal, Bill or Resolution
|
|
Health,
Intellectual Property
|
Communicating with government officials about regulations related to patented medicines, including the Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) under the Patent Act.
|
Regulation
|
|
Environment,
Health
|
Communicating with government officials about regulations related to safe and environmentally-responsible disposal of biopharmaceutical compounds, including the Food and Drug Regulations (C.R.C., c. 870) under the Food and Drugs Act.
|
Policies or Program
|
|
Health,
Intellectual Property
|
Communicating with government officials about regulations, guidelines reviews, references and reporting requirements issued by and/or related to the Patented Medicine Prices Review Board ("PMPRB").
|
Regulation
|
|
Health,
International Trade,
Science and Technology
|
Communicating with government officials about the Food and Drugs Act, more specifically about (i) export restrictions, (ii) cross-border trade of biopharmaceuticals, (iii) approval, regulation and life-cycle management of therapeutic products and (iv) data protection.
|
Legislative Proposal, Bill or Resolution
|
|
Health,
Intellectual Property
|
Communicating with government officials about the Patent Act, more specifically about the regulation of intellectual property for therapeutic products.
|
Legislative Proposal, Bill or Resolution
|
|
Health,
Science and Technology,
Taxation and Finance
|
Communicating with government officials about the Scientific Research and Experimental Development ("SR&ED") Tax Incentive Program, more specifically about investments in biopharmaceutical and health technology innovation.
|
Grant, Contribution or Other Financial Benefit
|
|
Health
|
Communicating with government officials about the development of a national pharmacare program with the goal of (i) improving patient well-being and health outcomes and (ii) improving access to effective treatments for patients.
|
Policies or Program
|
|
Health
|
Communicating with government officials about the modernization and improvement of Health Canada's "Progressive Licensing Framework".
|
Policies or Program
|
|
Health
|
Communicating with government officials, in general, about policies and programs related to improving access for Canadian patients to effective treatments for common mental health, addiction and neuro-degenerative conditions.
|
Policies or Program
|
|
Health
|
Communicating with government officials, in general, about programs, reports, reviews and policies issued by or related to Canada's Drug Agency (formerly known as the Canadian Agency for Drugs and Technologies in Health).
|
Policies or Program
|
|
Health,
Taxation and Finance
|
Communicating with government officials—including through the pan-Canadian Pharmaceutical Alliance (formerly known as the Pan-Canadian Pricing Alliance)—about drug pricing and reimbursement.
|
Policies or Program
|
| Subject matters | Details | Categories |
|---|---|---|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Institutes of Health (CIHR) initiatives, such as the Drug Safety and Effectiveness Network (DSEN), and various research programs, particularly as they relate to public/private research and development partnerships
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Data exclusivity as it relates to the use of Natural Health Products in biopharmaceutical preparations.
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Development of a Canadian National Pharmacare Program with a primary focus on improving patient well-being and health outcomes access to effective treatments for patients.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Environment and Climate Change Canada and/or Food and Drugs Act regulations as they relate to the safe and environmentally responsible disposal of biopharmaceutical compounds.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Existing or proposed policies and programs related to improving access to effective treatments for common mental health, addiction and neuro-degenerative for Canadian patients.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal Health Partnership with respect to the co-ordination of federal health benefit plan policies and programs.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal policies related to, and interactions with, the Canadian Agency for Drugs and Technologies in Health (CADTH) particularly pertaining to its Common Drug Review (CDR), Health Technology Assessment (HTA), and the Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) units.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drug Regulations as it relates to data protection (Section C.08.004) and the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act & regulations as they relate to export restrictions and cross border trade of biopharmaceuticals.
|
Legislative Proposal, Bill or Resolution,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
|
Legislative Proposal, Bill or Resolution
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada (including the Office of Patented Medicines and Liason (OPML)) policies and regulations with regards to therapeutic products
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health benefits programs of Immigration, Refugees and Citizenship Canada, Correctional Services of Canada, Health Canada (NIHB), the Department of National Defence, the Royal Canadian Mounted Police, and Veterans Affairs Canada with respect to decisions and policies which impact the reimbursement of biopharmaceutical therapeutic products for plan beneficiaries.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
International Trade Canada's "Invest in Canada" policies and programs with respect to investment, business development and innovation in the life sciences industry sector.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
International Trade policy initiatives related to implementing / strengthening the Canada-Europe Trade Agreement (CETA)and the Trans-Pacific Partnership (TPP), including recognition of patent term restoration within Canada's intellectual property protection regime
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Mobilizing Science and Technology to Canada's Advantage, the federal science and technology strategy, with respect to the health and related life sciences and technologies priority area
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Modernization of Health Canada's Progressive Licensing framework as it relates to the review and approval of biopharmaceutical products
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
National Pharmaceutical Strategy (NPS) as it relates to the federal government's involvement in the federal/provincial/territorial governments' access to medicines framework
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pan-Canadian Pricing Alliance as it relates to drug pricing and reimbursement.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act as it relates to the regulation of intellectual property for therapeutic products
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act with respect to Patented Medecines (Notice of Compliance (NOC)) Regulations and to Patented Medicines Regulations.
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines Prices Review Board (PMPRB) Regulations as they relate to reporting requirements and pricing guidelines as well as reference pricing and the modernization of PMPRB regulatory framework.
|
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program as it relates to investment in biopharmaceutical and related health technology innovation.
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: